Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 61 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016', provides in depth analysis on Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted pipeline therapeutics. 

The report provides comprehensive information on the Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) 
- The report reviews Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5

Introduction 6
Global Markets Direct Report Coverage 6
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) Overview 7
Therapeutics Development 8
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Products under Development by Stage of Development 8
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Products under Development by Therapy Area 9
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Products under Development by Indication 10
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Products under Development by Companies 13
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Companies Involved in Therapeutics Development 21
Chrysalis Pharma SAS 21
Griffin Discoveries BV 22
Johnson & Johnson 23
OSE Immunotherapeutics 24
Palau Pharma, S.A. 25
Sensorion S.A. 26
Ziarco Pharma Ltd 27
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Drug Profiles 28
GD-134 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
GD-136 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
GD-48 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
JNJ-28307474 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
JNJ-28610244 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
JNJ-40279486 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
SENS-218 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Small Molecules to Antagonize Histamine H4 Receptor for Vestibular Disorders - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
toreforant tartrate - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
tritoqualine - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
UR-63325 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
ZPL-389 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Dormant Projects 46
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Discontinued Products 49
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Featured News & Press Releases 50
Sep 19, 2016: Sensorion Presents Results of 2 Preclinical Trials at the 2016 IEB congress 50
Sep 07, 2016: Sensorion Announces Positive Results From SENS-218 Phase 1 Clinical Trial Undertaken in the UK 50
Sep 01, 2016: Sensorion Obtains FDA Approval to Initiate a Clinical Study of SENS-111 in Acute Severe Vertigo 51
Jun 13, 2016: Ziarco reports positive Phase 2a study results with ZPL-389 in moderate to severe atopic dermatitis patients 52
May 16, 2016: Ziarco Pharma Announces Positive Top Line Results from Phase 2a Study in Moderate to Severe Atopic Dermatitis with its Oral Lead Compound ZPL-389 53
May 12, 2016: Sensorion to Present Data from Phase 1b Clinical Trial of SENS-111 at AAO-HNSF Annual Meeting 53
Feb 22, 2016: Sensorion Presents SENS-218 Data at Association for Research in Otolaryngology Meeting 54
Feb 02, 2016: Phase 2a Psoriasis Study Initiated with Ziarco Lead Compound ZPL-389 55
Jan 06, 2016: Sensorion Receives Approval from the UK Drug Agency to Initiate Clinical Trial of SENS-218 55
Jun 10, 2015: Ziarco Initiates Phase 2a Clinical Trial of ZPL-389 in Atopic Dermatitis 56
Apr 23, 2015: Sensorion successfully completes the first part of the clinical trial on SENS-111, which aims to treat severe bouts of vertigo 57
Jun 18, 2014: Ziarco Secures £1.7M Grant from UK's Technology Strategy Board to Support Phase 2a of ZPL-389 in Atopic Dermatitis 58
Jun 08, 2010: Palau Pharma Reports Positive First-In-Man Phase I Clinical Trial Results For Its Histamine H4 Receptor Antagonist UR-63325 58

Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 60
Disclaimer 61

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Mechanism of Action, H2 2016 17
Number of Products by Stage and Route of Administration, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 20
Pipeline by Chrysalis Pharma SAS, H2 2016 21
Pipeline by Griffin Discoveries BV, H2 2016 22
Pipeline by Johnson & Johnson, H2 2016 23
Pipeline by OSE Immunotherapeutics, H2 2016 24
Pipeline by Palau Pharma, S.A., H2 2016 25
Pipeline by Sensorion S.A., H2 2016 26
Pipeline by Ziarco Pharma Ltd, H2 2016 27
Dormant Projects, H2 2016 46
Dormant Projects (Contd..1), H2 2016 47
Dormant Projects (Contd..2), H2 2016 48
Discontinued Products, H2 2016 49